Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161955 | 1.00 | KMT2A (0.62) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL6162598 | 1.00 | KMT2A (0.62) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL6162594 | 1.00 | KMT2A (0.62) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL6624940 | 1.00 | KMT2A (0.62) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL6162796 | 0.93 | KMT2A (0.62) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL2375730 | 0.89 | KMT2A (0.60) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL2375725 | 0.89 | KMT2A (0.60) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL8113033 | 0.88 | KMT2A (0.61) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL8113029 | 0.88 | KMT2A (0.61) | KMT2AMAPK1CTSSCTSKCTSL | |
| SCHEMBL6165554 | 0.87 | KMT2A (0.66) | KMT2AMAPK1CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828343-B2 | For therapy and prophylaxis of atherosclerosis, diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, hyperglycemia | PFIZER, INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1391460-A1 | Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1088824-B1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | disclosed |
| US-6576653-B2 | For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis | PFIZER INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, GYS1, PYGM | KMT2A 4190/4885MAPK1 1036/4885CTSS 680/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | KMT2A 3307/4885MAPK1 833/4885CTSS 2022/4885 |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | KMT2A 2831/4885MAPK1 2400/4885CTSS 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.